FDA Approves KEYTRUDA as First-Line Combination Therapy, Irrespective of PD-L1 Expression

Posted by ALCF Staff on May 10th, 2017
No Comments

Congratulations, Merck, for the approval of KEYTRUDA® in first-line combo therapy irrespective of PD-1 expression. The improved responses seen with KEYTRUDA® plus pemetrexed/carboplatin regimen are significant, and highlight the importance of finding new approaches that address the unmet needs of patients with metastatic nonsquamous non-small cell lung cancer.

Read the full press release here

About Guneet Walia, PhD

Dr. Guneet Walia is here to serve as your guide through what can feel like an overwhelming amount of information and jargon in lung cancer research. With her extensive background in oncology & drug development in the lab and experience working with cancer patients, she culls through the latest news to bring you the most important developments that can impact you and your disease today. If you have any questions, please don't hesitate to get in touch with Dr. Walia.

Comments are closed.